Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 11;146(6):450–462. doi: 10.1161/CIRCULATIONAHA.122.059150

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 2. — Changes in glomerular filtration rate, absolute proximal fluid reabsorption rate, absolute proximal sodium reabsorption rate, systolic blood pressure, diastolic blood pressure, and total peripheral resistance during screening subtracted from randomization and placebo subtracted from empagliflozin in patients with type 1 diabetes at baseline and in response to ramipril treatment after addition of empagliflozin or placebo. Changes in (A) glomerular filtration rate (GFR), (B) absolute proximal fluid reabsorption rate, (C) absolute proximal sodium reabsorption rate, (D) systolic blood pressure (SYSBP), (E) diastolic blood pressure (DIABP), and (F) total peripheral resistance (TPR) during screening subtracted from randomization and placebo subtracted from empagliflozin in patients with type 1 diabetes at baseline and in response to ramipril treatment after addition of empagliflozin or placebo.